Changing Treatment Paradigms for Solid Tumors
Delivering hope to patients with advanced pancreatic cancer and other aggressive solid tumors through innovative Live Biopharmaceutical (LBP) Technology.
Saltikva®
Saltikva® is our lead program in patients with Stage 4, metastatic pancreatic cancer. The Phase 2 results showed that Saltikva was shown to reduce tumor markers, tumor burden, and increase Progression Free Survival and Overall Survival when administered with modified FOLFIRINOX. No serious adverse reactions were caused by Saltikva in the clinical study.
Saltikva® will soon enter advanced clinical studies in pancreatic cancer and other aggressive solid tumors.
Novel Mechanism, Oral Delivery
Over 20 years of research, we believe that we have developed a safe vector to deliver the micro-factory for the production of cytokines within the tumor.
The production of target drugs intra-tumorally avoids potential complications and toxicity associated with the systemic administration of the same cytokines.
Additionally, our LBP vectors have been shown in animal studies to cause tumor destruction by two other, recognized modes of action, rendering our technology both safe and effective.
And yes — Saltikva® is orally administered.
Testimonials
Saltikva® Patient Interview
Behind every therapy is a story. This is one of them.
"When diagnosed, I did not want very toxic treatments leading to a little more time feeling rotten before dying…. Saltikva® is sort of like taking Lipitor, you'll likely have a good life for longer…"
— Compassionate Care Patient
Dr. Heller — Saltikva® Patient Testimonial, March 2025
Contact Us
For inquiries about Saltikva®, Expanded Access, investor relations, or general information about Salspera, please reach out to our team.
[email protected]